immune response biopharma - Latest Newshttp://news.prlog.org/tag/immune-response-biopharma/immune response biopharma - Latest News (Press Releases) - Read news before it's newsen-us3600 Immune Response BioPharma, Inc. to Seek Emergency Approval of REMUNE in Thailandhttp://www.prlog.org/12122820-immune-response-biopharma-inc-to-seek-emergency-approval-of-remune-in-thailand.htmlImmune Response BioPharma, Inc. to Seek Emergency Approval of REMUNE in Thailand & Begin Stockpiling HIV/AIDS Vaccine Immune Response BioPharma, Inc. to Seek Orphan Designation of NeuroVax for Pediatric MShttp://www.prlog.org/12097702-immune-response-biopharma-inc-to-seek-orphan-designation-of-neurovax-for-pediatric-ms.htmlImmune Response BioPharma, Inc. to Seek Orphan Designation of NeuroVax for Pediatric Multiple Sclerosis to Expand Use of Novel Vaccine Treatment. Immune Response BioPharma, Inc. Immune Response BioPharma, Inc. Selects American Stock Transfer & Trust as Transfer Agent of Recordhttp://www.prlog.org/12073824-immune-response-biopharma-inc-selects-american-stock-transfer-trust-as-transfer-agent-of-record.htmlImmune Response BioPharma, Inc. Selects the American Stock Transfer & Trust Company as Transfer Agent of Record. Immune Response BioPharma, Inc. Posts 2nd Half 2012 & Full Year Resultshttp://www.prlog.org/12054924-immune-response-biopharma-inc-posts-2nd-half-2012-full-year-results.htmlImmune Response BioPharma, Inc. Posts 2nd Half 2012 & Full Year Results Immune Response BioPharma, Inc. Files for Orphan Designation of REMUNE for Pediatric HIV/AIDShttp://www.prlog.org/12044245-immune-response-biopharma-inc-files-for-orphan-designation-of-remune-for-pediatric-hivaids.htmlImmune Response BioPharma, Inc. Files for Orphan Designation of REMUNE for Pediatric HIV/AIDS Immune Response BioPharma, Inc. New ZORCELL Psoriasis Vaccine Phase IIb Study Safety & Efficacyhttp://www.prlog.org/12040504-immune-response-biopharma-inc-new-zorcell-psoriasis-vaccine-phase-iib-study-safety-efficacy.htmlImmune Response BioPharma, Inc. Announces New ZORCELL Psoriasis Vaccine Phase IIb Study Safety & Efficacy 350 Patients ZORCELL + Methotrexate 6 Months Study. Immune Response BioPharma, Inc. Adopts Shareholder Rights Plan & Poison Pillhttp://www.prlog.org/12028587-immune-response-biopharma-inc-adopts-shareholder-rights-plan-poison-pill.htmlImmune Response BioPharma, Inc. Adopts Shareholder Rights Plan & Poison Pill Anti-Takeover Provision Immune Response BioPharma, Inc. REMUNE Effective 0.7% HIV Progression vs 6% Full 806 Study Resultshttp://www.prlog.org/12012807-immune-response-biopharma-inc-remune-effective-07-hiv-progression-vs-6-full-806-study-results.htmlImmune Response BioPharma, Inc. Publishes Phase III Full 806 Study Results, REMUNE Very Effective Demonstrating 0.7% HIV Progression vs 6% Estimated Rate & Subgroup Median Virologic Failure Delayed by 20 Weeks In REMUNE Group. Immune Response BioPharma, Inc. Business Update Sees Blockbuster MS NeuroVax Partnership by Q1 2013http://www.prlog.org/11986297-immune-response-biopharma-inc-business-update-sees-blockbuster-ms-neurovax-partnership-by-q1-2013.htmlImmune Response BioPharma, Inc. Provides Business Update Sees Blockbuster MS Drug NeuroVax the Gold Standard of Care for MS and a Partnership by the end of Q1 2013 REMUNE Effectiveness Extends Years After Inoculation REMUNE Patient Has 2 Healthy HIV Free Childrenhttp://www.prlog.org/11982962-remune-effectiveness-extends-years-after-inoculation-remune-patient-has-2-healthy-hiv-free-children.htmlREMUNE Effectiveness Extends Years After Inoculation REMUNE Injected Patient Has 2 Healthy HIV Free Children Proving the Vaccine has Strong Immune Responses a Decade Later Immune Response BioPharma, Inc. Sees First Year REMUNE Sales North of $1 Billion Dollarshttp://www.prlog.org/11956641-immune-response-biopharma-inc-sees-first-year-remune-sales-north-of-1-billion-dollars.htmlImmune Response BioPharma, Inc. Sees First Year REMUNE Sales North of $1 Billion Dollars Immune Response BioPharma, Inc. Review of Blockbuster RAVAX Phase 2B Study Patients 50% Improvementhttp://www.prlog.org/11923386-immune-response-biopharma-inc-review-of-blockbuster-ravax-phase-2b-study-patients-50-improvement.htmlImmune Response BioPharma, Inc. Review of Blockbuster RA Vaccine RAVAX Phase 2B 340 Patient Study Results Demonstrated a 50% Improvement in Patients Vaccinated with RAVAX. Immune Response BioPharma, Inc. Provides Blockbuster RAVAX Phase III Study in RA Updatehttp://www.prlog.org/11917251-immune-response-biopharma-inc-provides-blockbuster-ravax-phase-iii-study-in-ra-update.htmlImmune Response BioPharma, Inc. Provides Blockbuster RAVAX Phase III Study in RA Update With Inadequate Response to Humira or Enbrel now Available at www.immuneresponse.net Immune Response BioPharma, Inc. Posts 1st Half 2012 Resultshttp://www.prlog.org/11892240-immune-response-biopharma-inc-posts-1st-half-2012-results.htmlImmune Response BioPharma, Inc. Posts 1st Half 2012 Results Highlights include IRBP Granted U.S. Patent 8,053,197 for Auto-Immune Diseases & Plans for a Phase 2B NeuroVax Study and a Phase 3 RAVAX Study for RA. Immune Response BioPharma Terminates Blockbuster MS Drug NeuroVax Partnership Discussions with GSKhttp://www.prlog.org/11883928-immune-response-biopharma-terminates-blockbuster-ms-drug-neurovax-partnership-discussions-with-gsk.htmlImmune Response BioPharma, Inc. Terminates Blockbuster MS Drug NeuroVax Partnership Discusions With GSK Immune Response BioPharma, Inc. Is Granted U.S. Patent 8,053,197 for TCR Peptide Vaccine Technologyhttp://www.prlog.org/11873205-immune-response-biopharma-inc-is-granted-us-patent-8053197-for-tcr-peptide-vaccine-technology.htmlImmune Response BioPharma, Inc. announced today that it has received United States Patent Number 8,053,197 expanding coverage relating to its immune-based therapy for Treatment of Auto-Immune Diseases.